We have a broad and differentiated pipeline of investigational drugs across our family of companies.

We have run numerous large successful international Phase 3 clinical trials.
Agnostic to therapeutic area and modality
Our pipeline includes innovative product candidates across numerous therapeutic areas including immunology, oncology, hematology, and dermatology.
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Commercialization
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialization
Preclinical

Interested in learning more?
Discover how our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

Nimble, entrepreneurial Vants
Explore our diverse family of biopharmaceutical and health technology companies.